AnGes Inc 4563
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 49.00
- Day Range
- JPY 49.00–50.00
- 52-Week Range
- JPY 49.00–143.00
- Bid/Ask
- JPY 49.00 / JPY 50.00
- Market Cap
- JPY 9.86 Bil
- Volume/Avg
- 530,600 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 60.63
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 154
- Website
- http://www.anges.co.jp
Comparables
Valuation
|
Metric
|
4563
|
4893
|
8018
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.48 |
Price/Book Value | 0.37 | 1.32 | 0.73 |
Price/Sales | 60.63 | 22.64 | 1.49 |
Price/Cash Flow | — | — | 8.55 |
Price/Earnings
4563
4893
8018
Financial Strength
|
Metric
|
4563
|
4893
|
8018
|
|---|---|---|---|
Quick Ratio | 1.68 | 65.18 | 2.25 |
Current Ratio | 2.38 | 66.28 | 2.63 |
Interest Coverage | — | — | 64.05 |
Quick Ratio
4563
4893
8018
Profitability
|
Metric
|
4563
|
4893
|
8018
|
|---|---|---|---|
Return on Assets (Normalized) | −16.00% | −19.85% | 5.96% |
Return on Equity (Normalized) | −19.90% | −20.61% | 7.99% |
Return on Invested Capital (Normalized) | −19.26% | −20.61% | 6.22% |
Return on Assets
4563
4893
8018
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rzqbfmdssp | Nvczr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Txxjbphf | Tlnyxky | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hnzdjqgw | Gzhdrw | $97.8 Bil | |
MRNA
| Moderna Inc | Jmlvfqnf | Pxmc | $41.3 Bil | |
ARGX
| argenx SE ADR | Msyrqgxx | Llmm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jwlrwyc | Jnxvr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xqgfgwkls | Zmkvql | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nskbpzq | Wrnrb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dznkdvrjr | Dkcfbt | $12.5 Bil | |
INCY
| Incyte Corp | Glqqgqwhv | Ychvp | $11.6 Bil |